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Abstract
Background Better evidence regarding drug safety in the
pediatric population might be generated from existing data
sources such as spontaneous reporting systems and elec-
tronic healthcare records. The Global Research in Paedi-
atrics (GRiP)–Network of Excellence aims to develop
pediatric-specific methods that can be applied to these data
sources. A reference set of positive and negative drug–
event associations is required.
Key Points
A pediatric-specific reference set of positive and
negative drug–event associations was created.
The reference set may be utilized in evaluating
various data-mining methods, and databases.
It is important to determine locally, when the
positive associations became known, as this may
impact methods’ and database performance.
Objective The aim of this study was to develop a pedi-
atric-specific reference set of positive and negative drug–
event associations.
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Methods Considering user patterns and expert opinion,
16 drugs that are used in individuals aged 0–18 years were
selected and evaluated against 16 events, regarded as im-
portant safety outcomes. A cross-table of unique drug–
event pairs was created. Each pair was classified as po-
tential positive or negative control based on information
from the drug’s Summary of Product Characteristics and
Micromedex. If both information sources consistently
listed the event as an adverse event, the combination was
reviewed as potential positive control. If both did not, the
combination was evaluated as potential negative control.
Further evaluation was based on published literature.
Results Selected drugs include ibuprofen, flucloxacillin,
domperidone, methylphenidate, montelukast, quinine, and
cyproterone/ethinylestradiol. Selected events include bullous
eruption, aplastic anemia, ventricular arrhythmia, sudden
death, acute kidney injury, psychosis, and seizure. Alto-
gether, 256 unique combinations were reviewed, yielding 37
positive (17 with evidence from the pediatric population and
20 with evidence from adults only) and 90 negative control
pairs, with the remainder being unclassifiable.
Conclusion We propose a drug–event reference set that
can be used to compare different signal detection methods
in the pediatric population.
1 Introduction
In the last 50 years, drug safety monitoring has developed
rapidly in terms of increasing interest, broadening capacity,
innovation of methods and availability of data [1–3]. This
evolution has focused more on the adult population than
the pediatric age group (individuals aged 0–18 years).
However, drug safety monitoring in pediatrics is of par-
ticular importance because we continue to observe that
many drugs are prescribed unlicensed and there is lack of
adequate information on safety issues affecting this age
group. This is of particular concern as the impact of
adverse events during growth and maturation may be more
serious and longer term compared with adults [4–8].
Globally, specific regulations are being implemented to
generate better evidence on safety and efficacy in the
pediatric population, but mostly by clinical trials [9, 10].
Although useful for efficacy, such trials are usually too
small and with too short a follow-up to yield adequate
information on rare adverse drug reactions (ADR) and
long-term safety [11]. Therefore, other and preferably
existing data sources should be utilized to provide infor-
mation on the safety of drugs in pediatrics [12]. Existing
sources with lots of data comprise spontaneous reporting
system (SRS) and electronic healthcare record (EHR)
databases.
Although analysis of spontaneous reports is currently the
most commonly used method for identifying safety signals,
specific approaches to surveillance of the pediatric popula-
tion are limited. The Council for International Organizations
of Medical Sciences (CIOMS) Working Group VIII recently
advocated for an increased pediatric focus in signal detec-
tion [13]. CIOMS also suggested methods to control for
confounding in vaccines safety assessment, an issue specific
to the pediatric population, and de Bie et al. [14] proposed
further refinement of these methods.
Safety signal detection using SRS databases may be
complemented by mining longitudinal data in EHRs, as
described by the European Adverse Drug Reaction (EU-
ADR) project—‘Exploring and Understanding Adverse
Drug Reactions by Integrative Mining of Clinical Records
and Biomedical Knowledge’ and the ‘Observational Med-
ical Outcomes Partnership’ (OMOP) project [15–17].
Although newly developed methods, i.e. Longitudinal
Gamma Poisson Shrinker (LGPS), show promising results
in pediatric data [18], more extensive and systematic test-
ing is needed.
The Global Research in Paediatrics (GRiP)–Network of
excellence (http://www.grip-network.org/) was set up with
the general objective of facilitating the development and
safe use of medicines in the pediatric population, with a
specific objective being to apply innovative approaches and
standardized methodologies, as well as better utilization of
existing healthcare and spontaneous reporting databases.
GRiP aims to tailor existing signal detection methods to
pediatric safety data. Comparison of the performance of
existing methods within and across SRS and EHR
databases is the first step in defining suitable methods to be
implemented. For this purpose, creation of a reference set
comprising pediatric-specific drug–event pairs serving as
positive and negative control, is required to calculate
baseline performance statistics. Coloma et al. [19] recently
described the methodology for creating a reference set used
to test methods in the EU-ADR project. Similarly, Ryan
et al. [20] established a reference set for testing methods in
the OMOP project. However, both were not specific to the
pediatric population and comprise many drugs infrequently
prescribed within this age group, and events that rarely (or
never) affect them.
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In this study we describe how we created a proposed
reference set for comparing the performance of different
methods in detecting drug safety signals in the pediatric
population. This may be used for spontaneous reporting, as
well as electronic healthcare record databases.
2 Methods
The first step in creating the reference set was to select a
list of eligible drugs to be utilized. Based on four criteria,
four (primary) lists of drugs were created: we compiled
drugs that are frequently prescribed in pediatrics (including
off-label use), on an outpatient basis in high-income
countries (as per papers and reports of use) [21, 22]; to
allow for inpatient databases to be assessed, we included
drugs that are administered to hospitalized persons aged
0–18 years (or administered by specialists) [22]; to allow
for databases from low- and middle-income countries
(LMICs) to be assessed, we included drugs that are used in
such countries [as per the World Health Organization
(WHO) List of Essential Medicines for children] [23]; and
to allow for testing signal detection performance by dif-
ferent age groups, we included drugs that are used in
specific pediatric age groups (for example, adolescents)
[22].
To obtain a final drug list, a stepwise procedure was
implemented. First, if two or more drugs [fifth-level che-
mical substances, WHO Anatomical Therapeutic Chemical
(ATC) Classification System] belonged to the same class
(‘WHO-ATC, fourth level’), and were listed in an equal
number of primary lists ([1), we preferentially selected
only the drug that had the oldest initial marketing autho-
rization worldwide. This was done to have the most evi-
dence available. For example, doxycycline (WHO-ATC
code J01AA02) would be selected instead of minocycline
(WHO-ATC code J01AA08) because although they both
belong to the same class—‘WHO-ATC, fourth level’
(tetracyclines)—doxycycline was first marketed in 1967
[24], and minocycline in 1972 [25]. Second, we preferen-
tially selected drugs that appeared in most of the lists, for
example a drug appearing on three of four primary lists
would be retained instead of another drug appearing on
only two lists. The final list comprised more than 30 drugs,
which was beyond our capacity and resources and was
reduced to 16 for pragmatic reasons.
Events were chosen (independent of the drugs) with the
aim of generating a set which may be used for methods
development on spontaneous reporting as well as EHRs.
Both rare and common events were included to allow for
investigation of effect modification. Starting with common
adverse events observed in pediatrics, as reported by Star
et al. [26], we selected only events that were deemed
serious (as per the WHO definition [27]) and specific (to
avoid misclassification). For example aplastic anemia was
selected rather than anemia as the former connotes a more
serious and specific medical condition. Some events (i.e.
psychosis and seizure) were included by consensus in the
research team because they were considered relevant for
the pediatric population from a pharmacovigilance and
public health point of view. Fifteen drugs and events were
considered as the minimum required for generating enough
positive and negative associations. Finally, the total num-
ber of drugs and events was set at 16 for pragmatic reasons.
Four researchers (MS, IW, JB, and GJ) with a range of
expertise spanning pediatrics, pharmacology, and pharma-
coepidemiology determined the final list of selected drugs
and events. MS and IW are pharmacists/pharmacoepi-
demiologists, JB is a pediatrician, and GJ is a pediatri-
cian/clinical pharmacologist/pharmacoepidemiologist.
All events of interest were defined using standard
resources (i.e. medical textbooks, uptodate.com, and sci-
entific societies such as the CIOMS) to increase the like-
lihood of comprehensive literature searches. The final
reference set was generated by cross-tabulating the final
lists of drugs and events, which led to a matrix of 256
unique drug–event pairs. In order to classify each unique
drug–event pair as a ‘positive’, ‘negative’, or ‘unclassifi-
able’ association, evidence was reviewed in two sequential
steps.
2.1 Review of Summary of Product Characteristics
(SPC) and Micromedex
First, two researchers (OO and CF) with expertise in general
medicine, pharmacy, and pharmacoepidemiology reviewed
the SPC of each drug to ascertain that a specific event (for
example, aplastic anemia) was listed as a possible adverse
event under the appropriate section(s)—‘Undesirable
effects’ (section 4.8) and/or ‘Special warnings and
precautions for use’ (section 4.4) from the electronic
Medicines Compendium (eMC) [28]. DailyMed (the ‘Con-
traindications, Warnings, Precautions’ and/or ‘Adverse
Reactions’ sections) was consulted only if a drug was not
listed in the eMC [29]. The eMC contains more than 9,000
up-to-date, freely accessible documents containing infor-
mation about medicines licensed for use in the UK. Prior to
publishing, these documents are usually checked and
approved by either the UK Medicines and Healthcare
products Regulatory Agency (MHRA) or the European
Medicines Agency (EMA). DailyMed, published by the
National Library of Medicine (NLM) in the US, contains
up-to-date information about drugs licensed for use in the
US. Both eMC and DailyMed are freely accessible online.
Second, two researchers (OO and CF) reviewed
Micromedex to check if the event was listed under the
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section ‘Adverse Reactions’ within the Drugdex compo-
nent. Micromedex is an online drug information system
that contains referenced information from various sources
needed for clinical decision making, including adverse
effects of drugs (http://www.micromedex.com/).
After reviewing the SPC and Micromedex, drug–event
pairs were classified as (1) ‘potential positive control’
(event was mentioned in both the SPC and Micromedex);
(2) ‘potential negative control’ (event was mentioned in
neither the SPC nor Micromedex); or (3) unclassifiable
(discordant information between the SPC and Micro-
medex). ‘Potential positive control’ and ‘potential negative
control’ pairs were retained and the relationship of each
drug–event pair was further evaluated using published lit-
erature (Fig. 1).
2.2 Review of Published Literature
For each drug–event pair that was classified as a ‘potential
negative control’, a systematic literature search was con-
ducted in EMBASE.COM and MEDLINE (via OvidSP).
The sensitive search algorithm applied to both title and
abstract comprised controlled vocabulary plus free text for
each of two concepts: ‘event of interest’ and drug.
For each ‘potential positive control’, the search algo-
rithm was more specific (to avoid large numbers of papers)
than for the potential negative controls, and included only
controlled vocabulary for the drug name. However, the
event was searched by using both controlled vocabulary
and free text. In addition, controlled vocabulary was
included for the concept ‘general adverse drug reaction’;
this was done to increase the probability of retrieving only
those articles where adverse event and drug co-occurred in
the context of drug safety [19].
For potential negative and positive control pairs we only
considered articles published in English. Publications could
be biological and/or epidemiological studies. Epi-
demiological studies could be case reports, observational
studies (i.e. cohort, case-control), reviews, meta-analysis,
and clinical trials. As an example, the search strings for the
negative control sudden death–cyproterone/ethinylestradi-
ol, and positive control sudden death–clarithromycin are
presented in Appendix 1 of the electronic supplementary
material (ESM).
One of five researchers (OO, CF, FF, MC, and YH)
reviewed retrieved publications pertaining to a unique
drug–event pair. All five researchers have received medi-
cal, biological, and/or pharmacology training. Based on
check SPC and 
Micromedex
query medline and 
embase.com (17685 hits)
FINAL REFERENCE SET 127#
yes/yes no/no
no evidence
sufficient 
evidence evidence discordant with  
SPC/Micromedex
yes/no no/yes
16 drugs 
discard as 
‘unclassifiable’
discard as 
‘unclassifiable’ 95#
256 unique drug-event 
pairs 16 events
consider for POSITIVE
CONTROL 95#
consider for NEGATIVE 
CONTROL 127#
confirm as POSITIVE
CONTROL 37#
confirm as NEGATIVE 
CONTROL 90#
Fig. 1 Procedure adopted for the construction of the reference set (adapted from Coloma et al. [19]). SPC Summary of Product Characteristics,
# drug–event pairs
210 O. U. Osokogu et al.
data extracted from relevant publications, unique drug–
event pairs were classified according to the criteria outlined
in Table 1. For example, a pair was assigned level I evi-
dence if there was evidence from at least one randomized
controlled trial or meta-analysis, while ‘positive control,
grade 1’ (PC1) meant that in addition there was ‘proven
biological mechanism for causal association’. Level V
evidence—(not mentioned in the SPC/Micromedex) AND
(published evidence against causal association; OR no
published evidence supporting causal association)—quali-
fied a specific drug–event pair as a negative control, while
‘negative control, grade 1’ (NC1) meant that in addition
there was ‘proven biological mechanism against causal
association’. ‘Proven biological mechanism’ meant that
there was at least one publication providing relevant bio-
logical evidence regarding a unique drug–event pair.
Two researchers (MS and FK; a pediatrician, clinical
pharmacologist, and pharmacoepidemiologist) reviewed all
associations that were classified as positive or negative
control.
Whereas confirmation of negative control pairs required
lack of association for either adults or the pediatric age
group, positive control pairs were specifically assessed for
availability of evidence pertaining to persons aged 0–18
years. However, such evidence was not mandatory for
classification as positive control due to the acknowledged
lack of pediatric-specific studies [30]. Those with lack of
evidence in pediatrics are listed separately.
To further illustrate the process of reviewing the pub-
lished literature, 126 unique references were retrieved
following database search for articles supporting the po-
tential positive control sudden death–clarithromycin. Of
these, 103 articles were excluded following title/abstract
screening, while 13 articles were excluded following full-
text screening. Full-text copies of six articles could not be
obtained. Finally, four articles––one clinical trial, two
case-control studies, and one case report––presented suf-
ficient evidence to support the association.
3 Results
As presented in Table 2, 16 drugs (unique WHO-
ATC codes, fifth-level chemical substance) were selected
for the reference set, comprising eight anti-infectives: flu-
cloxacillin, clarithromycin, doxycycline, lopinavir (which
is always administered in fixed-dose combination with
ritonavir), isoniazid, praziquantel, mebendazole, and qui-
nine. The remaining were respiratory drugs (fluticasone,
administered as an inhalant, and montelukast), gas-
trointestinal drugs (loperamide and domperidone), anti-
pyretic/analgesic (ibuprofen), a drug for attention-deficit
hyperactivity disorder (methylphenidate), anti-acne T
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(isotretinoin), and a hormonal oral contraceptive (cypro-
terone/ethinylestradiol).
We selected 16 events for the reference set—bullous
eruption [comprising fixed drug eruption (FDE), erythema
multiforme (EM), Stevens–Johnson syndrome (SJS), and
toxic epidermal necrolysis (TEN)], aplastic anemia,
agranulocytosis, thrombocytopenia, psychosis, suicide,
ventricular arrhythmia, sudden death, QT prolongation,
venous thromboembolism, anaphylaxis, seizure, acute
kidney injury (AKI), acute liver injury (ALI), sepsis, and
sudden infant death syndrome (SIDS) (Table 2). Medical
definitions for all events and their proposed (unvalidated)
Medical Dictionary for Regulatory Activities (MedDRA)
codes are presented in Appendix 2 of the ESM.
From the total number of combinations (256), we dis-
continued assessment of 34 unclassifiable drug–event pairs
since we found discrepant information between the SPC
and Micromedex. For the remaining 222 pairs, the lit-
erature search generated 17,685 hits. Based on review of
these hits, 127 pairs were confirmed as positive control (37
pairs) or negative control (90 pairs) (Tables 2, 3); for 95
‘unclassifiable’ pairs there was discrepant information
between the published literature on one hand and the SPC
and Micromedex on the other hand.
In confirming the 37 positive controls, evidence was used
from 171 relevant publications, comprising 14 biological
studies, 10 clinical trials, 23 observational studies, 34
reviews, and 90 case reports/series. The association between
quinine and thrombocytopenia had the highest number of
supporting publications, i.e. 20 (of 171); eight publications
pertained to biological evidence, while 12 reported on epi-
demiologic evidence. Table 4 shows how the positive con-
trols (quinine–thrombocytopenia and clarithromycin–
sudden death) were established. For complete evaluation of
all positive controls, see Appendix 3 of the ESM.
As presented in Table 3, we generated 37 positive
controls; of these, level I evidence was available for only 8
(22 %), and 13 (35 %) were supported by both biological
and epidemiological evidence. Only four associations
(clarithromycin–thrombocytopenia, montelukast–psychosis,
montelukast–suicide AND methylphenidate–psychosis)
were supported by evidence generated exclusively from the
pediatric age group, while 13 associations were supported
by evidence from both adults and the pediatric popula-
tion. Overall, 17 (46 %) of all positive associations
were based on evidence from the pediatric population.
Twenty associations were supported by evidence from only
adults.
As presented in Appendix 4 of the ESM, we compared
the reference set we created with the reference sets that
were created within EU-ADR and OMOP. Of the 16 drugs
that were selected for GRiP, four were also included in EU-
ADR and/or OMOP: fluticasone, ibuprofen, isoniazid, and
mebendazole. Ibuprofen was classified to be a positive
control for AKI in each of the three reference sets, while
the same drug was classified to be associated with ALI only
Table 2 Classification of each drug–event pair as positive control (green: PC1 or PC2) or negative control (red: NC2)
Abbreviations: Vent. - ventricular; SIDS - Sudden Infant Death Syndrome; eth.est.- ethinylestradiol
Selected Adverse Events
Bullous 
eruption
Aplastic 
anemia
Agranulo
cytosis
Thromboc
ytopenia
Psycho-
sis
Sui-
cide
Vent. 
arrhyth-
mia
Sudden
death
QT 
prolon-
gation
Venous 
thrombo-
embolism
Anaphyl
axis Seizure
Acute 
kidney 
injury
Acute 
liver 
injury
Sepsis SIDS
Se
le
ct
ed
 D
ru
gs
flucloxa-
cillin
clarithro-
mycin
doxycy-
cline
lopina-
vir
isonia-
zid
prazi-
quantel
meben-
dazole
quinine
flutica-
sone
monte-
lukast
isotreti-
noin
lopera-
mide
dompe-
ridone
methyl-
phenidate
ibupro-
fen
cyproterone
/eth.est.
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Table 3 Level of epidemiological and biological evidence; population in which association was found (adults, ‘children’a, or both) and grading
of positive drug–event associations
Event Positive associations
ATC code Drug name Level of
epidemiological
evidencec
Population
(A/B/C)d
Biological
evidence (Pr/Pl)
Gradee
Bullous eruptionb J01FA09 Clarithromycin II B Pl PC2
J01CF05 Doxycycline II B Pl PC2
J04AC01 Isoniazid II B Pl PC2
P01BC01 Quinine II A Pl PC2
M01AE01 Ibuprofen II B Pl PC2
Aplastic anemia P01BC01 Quinine II A Pr PC1
Agranulocytosis P02CA01 Mebendazole II A Pl PC2
P01BC01 Quinine II A Pr PC1
Thrombocytopenia J01FA09 Clarithromycin II C Pl PC2
J01CF05 Doxycycline I A Pl PC2
P01BC01 Quinine II A Pr PC1
M01AE01 Ibuprofen I A Pl PC2
Psychosis J01FA09 Clarithromycin II A Pl PC2
J04AC01 Isoniazid II A Pl PC2
R03DC03 Montelukast II C Pl PC2
D10BA01 Isotretinoin II B Pr PC1
N06BA04 Methylphenidate I C Pr PC1
Suicide R03DC03 Montelukast II C Pl PC2
D10BA01 Isotretinoin II B Pr PC1
Ventricular arrhythmia J01FA09 Clarithromycin II A Pl PC2
P01BC01 Quinine II A Pl PC2
A03FA03 Domperidone II A Pr PC1
Sudden death J01FA09 Clarithromycin I A Pl PC2
A03FA03 Domperidone II A Pr PC1
QT prolongation J01FA09 Clarithromycin II A Pr PC1
P01BC01 Quinine I B Pr PC1
Anaphylaxis M01AE01 Ibuprofen II B Pr PC1
Seizure J04AC01 Isoniazid II B Pr PC1
Acute kidney injury P01BC01 Quinine II A Pl PC2
M01AE01 Ibuprofen II B Pr PC1
Acute liver injury J01CF05 Flucloxacillin II A Pl PC2
J01FA09 Clarithromycin II B Pl PC2
J05AE06 Lopinavir I A Pl PC2
J04AC01 Isoniazid I B Pl PC2
P02CA01 Mebendazole I B Pl PC2
P01BC01 Quinine II A Pl PC2
M01AE01 Ibuprofen II A Pl PC2
ATC Anatomical Therapeutic Chemical, Pr proven biological evidence, Pl plausible biological evidence, PC positive control
a In this context ‘Children’ refers to individuals aged 0–18 years
b Epidemiological evidence levels I and II are defined in Table 1
c Population in which epidemiological evidence was found: A, adults; B, both adults and ‘children’; C, ‘children’
d As defined in Table 1
e Bullous eruption includes fixed drug eruption, erythema multiforme, Stevens–Johnson syndrome, and toxic epidermal necrolysis
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within GRiP and EU-ADR. Isoniazid was classified as
positive control for ALI, both in GRiP and OMOP. Neither
OMOP nor EU-ADR labeled mebendazole with AKI, nor
fluticasone with ALI.
4 Discussion
We describe a pediatric-focused reference set of drug–
event associations that may be used for testing the per-
formance of different signal detection methods and
databases. To our knowledge, this is the first structured
approach to creating a reference set that is specific to
pediatric safety outcomes. This approach yielded 37 posi-
tive and 90 negative drug–event associations; 17 positive
associations were supported by evidence in pediatric age
group, and 20 were based on adult information only.
Projects such as OMOP and EU-ADR have also created
reference sets but none was targeted to pediatrics; in
addition, the construct of these reference sets was different
[19, 31–33]. In the current project, drugs and events were
selected independently, unlike EU-ADR and OMOP [19,
20]. In addition, the EU-ADR network restricted the list of
drugs based on the amount of drug exposure that would be
required to identify associations with selected adverse
events at pre-specified relative risk (RR) values. This was
done so that such drug–event associations could actually be
identified if indeed they occurred within the network.
Similar calculations were not done for the current project,
although most of the selected drugs are frequently admin-
istered in the pediatric population (based on reported evi-
dence in the literature). Furthermore, the reference set
resulting from the current project will be applied to SRS
databases (in addition to EHRs) and therefore should
preferably be unbiased to one or the other.
The GRiP reference set focused on diversity of drugs
and events which may allow us to stratify by outpatient/
inpatient care, and frequent and rare events. Sets with drugs
for inpatient use may favour performance of data mining
on SRS databases, while sets utilizing drugs prescribed for
outpatient treatments may favour mining performance on
EHR databases [34]. In order to have enough power for
both, we focused on drugs with longer license status.
In selecting adverse events, we considered both frequent
and rare events. Thus, the resulting reference set can be
tested in a wide variety of databases with unique adverse
event profiles, such as SRSs, and hospital-based and gen-
eral practice healthcare databases. Previous reference sets
focused mostly on rare and well-known drug-induced
events which may favour SRSs [19]. Such events may be
reported more often than common, multifactorial events
because they are easier to identify as being caused by
drugs. Given that the composition of the lists of drugs and
adverse events to be tested may have an extensive impact
on performance assessment [35], we tried to ensure that the
criteria and data sources that were utilized to create the
reference set were independent of the data on which they
will eventually be tested.
We conducted extensive reviews to list evidence for
both positive and negative controls. Fewer publications
were retrieved for the potential positive control pairs (7,745
hits) compared with the potential negative control pairs
(9,940 hits), possibly because the search algorithm for the
former was more specific. However, this was considered
Table 4 Examples of evaluation of a positive drug–event association: (1) quinine–thrombocytopenia and (2) clarithromycin–sudden death
ATC code Drug name Event type Labeled as AE in SPC (yes/no) Type/no. of supporting
literature citations
P01BC01 Quinine Thrombocytopenia Yes
*eMC (special warnings and precautions
for use; undesirable effects)
#Micromedex (summary): black-box
warning; (contraindications/
warnings ? contraindications;
precautions); (adverse effects ? serious)
Total number of supporting
citations = 20
Biological studies = 8
Review of biological studies = 4
Systematic review = 1
Case-series = 1
Case reports = 4
Review of spontaneous reports = 2
J01FA09 Clarithromycin Sudden death Yes
*eMC (undesirable effects)
#Micromedex (summary):
(contraindications/warnings ?
precautions); (adverse effects ? serious)
Total number of supporting
citations = 4
Clinical trial = 1
Case-control = 2
Case report = 1
ATC Anatomical Therapeutic Chemical, AE adverse effect, SPC Summary of Product Characteristics, eMC electronic Medicines Compendium
* https://www.medicines.org.uk/emc/
# http://micromedex.com/
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necessary to increase the probability of retrieving relevant
publications (i.e. publications that reported on adverse
event and drug in the context of drug safety), an approach
similar to that adopted by the EU-ADR project [19].
To validate potential negative control pairs, terms that
were related to the actual event term were considered. For
example suicide–isoniazid was initially classified as
potential negative control because suicide was not men-
tioned (in relation to isoniazid), both in the SPC (DailyMed)
and Micromedex. However, a case report described the
occurrence of suicide attempt following ingestion of
isoniazid [36]; therefore, this association could not be
confirmed as negative control. Whereas the negative drug–
event associations required lack of association for adults
or the pediatric population, the positive drug–event
associations were specifically (or primarily) assessed for
availability of evidence pertaining to the pediatric age
group. However, due to the general lack of pediatric
pharmacoepidemiological data, only four associations
(clarithromycin–thrombocytopenia, montelukast–psychosis,
montelukast–suicide AND methylphenidate–psychosis)
were supported by evidence generated exclusively from this
age group: a case-control study for clarithromycin–throm-
bocytopenia [37]; case reports (more than three) for mon-
telukast–psychosis [38]; review of spontaneous reports for
montelukast–suicide [39]; and clinical trials as well as case
series for methylphenidate–psychosis [40]. The scarcity and
quality of pediatric-specific data further highlight the dif-
ficulties in generating safety evidence in the pediatric
population, thereby underlining the importance of devel-
oping a tool to define appropriate signal detection methods
in this population. We recommend that the 20 positive
associations that come from adult evidence only, be treated
separately in the performance testing in pediatric data.
We chose to classify all pairs with inconsistent evidence
as unclassifiable, to avoid misclassification. We searched
for biological (in addition to epidemiological) evidence to
further strengthen retrieved evidence for positive controls.
However, we were able to find such evidence for only 13 of
37 positive associations: quinine–aplastic anemia [41];
quinine–agranulocytosis [42]; quinine–thrombocytopenia
[43]; isotretinoin–psychosis [44, 45]; methylphenidate–
psychosis [46, 47]; isotretinion–suicide [44, 45]; dom-
peridone–ventricular arrhythmia [48]; domperidone–sud-
den death [49]; clarithromycin–QT prolongation [50];
quinine–QT prolongation [51, 52]; ibuprofen–anaphylaxis
[53]; isoniazid–seizure [54]; and ibuprofen–AKI [55]. Of
these, quinine–thrombocytopenia had the highest number
of supporting publications, i.e. eight regarding biological
evidence (in addition to 12 others pertaining to epi-
demiological evidence). This is possibly because quinine
has been in use for a long time, both as over-the-counter
(OTC) and prescription drug [56]; therefore, its safety
profile has been well investigated. Otherwise, the limited
biological evidence for most of the other positive asso-
ciations may reflect the current gap of knowledge and
understanding of ADRs.
Comparing our reference set with others, we found little
overlap in the choice of drugs, possibly because we aimed
to be pediatric-specific in our selection while also including
drugs used in specific subpopulations (i.e. adolescents) and
context (LMICs). Of 16 drugs considered in GRiP, only
four were also considered in EU-ADR and/or OMOP:
isoniazid, ibuprofen, mebendazole, and fluticasone. Per-
haps this, as well as differences in adverse event selection,
explains the few similarities we found across the three
reference sets. Nevertheless, ibuprofen was found to be
associated with AKI in all sets.
There are several limitations in the creation and use of a
reference set. Some potential positive associations that are
well known (i.e. domperidone–QT prolongation and cypro-
terone/ethinylestradiol–venous thromboembolism, both of
which have been well investigated) could not be validated.
The search query we used to retrieve the publications may
have been too specific. For other unconfirmed potential
positive control pairs, events mentioned in the SPC and
Micromedex may have been reported through means other
than peer-reviewed literature (for example, US FDA reports).
Time is an important limiting aspect in building a ref-
erence set, both for the positive as well as negative con-
trols. We labeled drug–event associations as negative if
there was lack of evidence, which in itself is something that
may rapidly change over time; checking of the absence of
evidence should always be carried out prior to using the
reference set. For the positive controls, it is important to
know at which point in time the association was ‘known’ as
this may lead to changes in reporting behaviour to spon-
taneous reporting databases and to changes in clinical care.
Those changes may have an impact on the ability to detect
associations (for example, in spontaneous reporting
databases it may increase the association, whereas it may
decrease in electronic healthcare databases) [57–59]. Time
stamping of the ‘known’ associations would be important.
However, this was impossible for this reference set since
we chose drugs that are available for a long time and have
been registered nationally. Inclusion of information in an
SPC may vary from country to country. We recommend
investigators who will use this set, to assess in their reality
when associations were ‘known’ in order to evaluate the
impact of that on performance.
In order to use the reference set, the events need to be
translated into codes. This is an important step and may
impact on the performance testing. In Appendix 2 of the
ESM we have provided initial MedDRA codes as most of
the events have Standardised MedDRA Queries (SMQs).
These codes should be reviewed and the impact of choices
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should be carefully evaluated; they may differ between
spontaneous reporting databases and EHRs. Within the
GRiP project, we aim to perform this work for MedDRA,
International Classification of Diseases, Ninth Revision
(ICD-9), ICD, Tenth Revision (ICD-10), READ and
International Classification of Primary Care (ICPC), and a
full code list with the impact of choice on performance will
become available later.
5 Conclusions
We have generated a pediatric-focused reference set that
can be applied for testing performance of methods and
databases for drug safety signal detection in the pediatric
population. This reference set may be viewed as dynamic.
The status of drug–event associations may change over
time, particularly as more evidence derived specifically
from the pediatric population becomes available in the
future. Therefore, periodic review and checking against the
local situation is advisable.
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